ClinicalTrials.gg
CompletedNCT01881230tnAcityUpdated Feb 21, 2019Results posted

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

A Phase 2/3 interventional study of nab-Paclitaxel and Carboplatin in Breast Tumor, Breast Cancer and Cancer of the Breast, sponsored by Celgene. Completed at 140 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-21.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Albumin-Bound Paclitaxel · Triple Negative Breast Neoplasms.

Enrollment
4th of 25
191 · median 64
Started
2013
the only one that year
Phase 2/3
2 of 25
none open now
Registered
5th of 25
by date
Lead sponsor
2 of 25
Celgene

Among the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 2/3, and was the 5th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

7 of the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.

Read the detailed description

ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. In the phase 2 portion of the study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be compared to gemcitabine combined with carboplatin to evaluate progression free survival, safety and tolerability, overall survival, disease control rate and duration of response in women with metastatic triple negative breast cancer.

Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.

03

Conditions studied

  • Breast Tumor
  • Breast Cancer
  • Cancer of the Breast
  • Estrogen Receptor- Negative Breast Cancer
  • HER2- Negative Breast Cancer
  • Progesterone Receptor- Negative Breast Cancer
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer
  • Triple-negative Breast Cancer
  • Triple-negative Metastatic Breast Cancer
  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Cancer of the Breast
  • Metastatic Breast Cancer
  • Metastatic Triple Negative Breast Cancer
  • Triple Negative Breast Cancer
  • Triple Negative Metastatic Breast Cancer
  • Basal-like breast cancer
  • Hormone receptor negative breast cancer
  • Estrogen receptor negative breast cancer
  • Progesterone negative receptor breast cancer
  • HER2 Negative Breast Cancer
  • Abraxane
  • nab-Paclitaxel
  • ABI-007
  • gemcitabine
  • Gemzar
  • carboplatin
  • Paraplatin
  • Paraplatin AQ
  • Phase 2
  • Phase 3
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

This study's enrollment of 191 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria are met:

  1. Female subjects, age ≥ 18 years at the time is signed
  2. confirmed adenocarcinoma of the breast
  3. Pathologically confirmed as triple negative, source documented, defined as both of the following

    1. Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: \< 1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls)
    2. Human Epidermal Growth Factor Receptor 2 () negative as per American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines i. Immunohistochemistry (IHC) 0 or 1 Fluorescence In Situ Hybridization (FISH) negative (or equivalent negative test). Subjects with IHC 2 must have a negative by Fluorescence In Situ Hybridization (FISH),, (or equivalent negative test).
  4. Subjects with prior breast cancer history of different phenotypes (ie, ER/PgR/HER2 positive) must have pathologic confirmation of triple negative disease in at least one of the current sites of
  5. Subjects must have received prior or neoadjuvant anthracycline therapy; unless (a) anthracycline treatment was not indicated or was not the best treatment option for the subject in the opinion of the treating physician; and (b) anthracycline treatment remains not indicated or, in the opinion of the treating physician, is not the best treatment option for the subject's metastatic disease.

    a. Newly diagnosed subjects presenting with TNMBC are eligible for the study if anthracycline treatment is not indicated or is not the best treatment option for the subject in the opinion of the treating physician.

  6. Subjects with measurable metastatic disease, defined by 1.1 (RECIST 1.1) guidelines
  7. ≥ 16 weeks from randomization
  8. No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy and/or monoclonal antibody therapy are acceptable. Prior treatments must have been discontinued at least 30 days prior to start of study treatment and all related toxicities must have resolved to Grade 1 or less.
  9. Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at least 6 months before randomization with all related toxicities resolved, and documented evidence of disease progression per RECIST 1.1 guidelines is required.

    a. If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or platinum agents, the treatment must have completed at least 12 months before randomization

  10. Prior radiotherapy must have completed before randomization, with full recovery from acute radiation side effects. At least one must be completely outside the radiation portal or there must be unequivocal radiologic or clinical exam proof of progressive disease within the radiation portal, in accordance with RECIST 1.1 guidelines
  11. At least 30 days from major surgery before randomization, with full recovery
  12. (ECOG) performance status 0-1
  13. Subject has the following blood counts at screening:

    • (ANC) ≥ 1500/mm\^2 ;
    • ≥ 100,000/mm\^2 ;
    • (Hgb) ≥ 9 g/dL
  14. Subject has the following blood chemistry levels at screening:

    • (AST) Serum glutamic-oxaloacetic transaminase (SGOT), Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) ≤ 2.5 x (ULN); if hepatic metastases present ≤ 5.0 x ULN
    • Total serum ≤ ULN; or total bilirubin ≤ 3.0 × ULN with direct bilirubin within normal range in subjects with documented Gilbert's Syndrome
    • > 60 mL/min (by Cockcroft-Gault)
  15. Females of [defined as a sexually mature women who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:

    • Demonstrate a negative serum pregnancy test result at screening (performed by central lab) confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of IP); pregnancy test with sensitivity of at least 25 mIU/mL; and
    • Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, two physician approved effective methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) without interruption for 28 days or longer as required by local guidelines, prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of the study or longer as required by local guidelines
  16. Females must abstain from breastfeeding starting at randomization, during study participation and for 28 days or longer as required by local guidelines, after IP discontinuation
  17. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
  18. Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Male subjects
  2. Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior immunotherapy \& monoclonal antibody therapy are acceptable.
  3. Subjects who received prior cytotoxic chemotherapy after incomplete resection of locoregional recurrent disease
  4. History of, or known current evidence of , including .
  5. Subjects with bone as the only site of metastatic disease
  6. Subjects with regional lymph node as the only site of metastatic disease
  7. Serious intercurrent medical or psychiatric illness, including serious active infection
  8. History of class II-IV congestive heart failure or myocardial infarction within 6 months of randomization
  9. History of other primary in the last 5 years prior to randomization. Subjects with prior breast cancer history are eligible, however, the most recently obtained must demonstrate triple negative disease (source documented). Subjects with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.
  10. Subjects with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary pneumonitis or multiple uncontrolled or unstable allergies which, in the opinion of the investigator, may lead to serious complications
  11. Peripheral neuropathy Grade ≥ 2 by National Cancer Institute (NCI CTCAE) v4.0
  12. Subjects who have received an product within the previous 4 weeks prior to randomization
  13. Subject is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
  14. Pregnant or nursing women
  15. Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or any other platin, or nucleoside analogue agents
  16. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if she were to participate in the study
  18. Any condition that confounds the ability to interpret data from the study
  19. History of seropositive (HIV)
  20. Subjects who are receiving or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    nab-Paclitaxel plus Gemcitabine

    Treatment Arm A: nab-Paclitaxel 125 mg/m\^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes

    Drug: nab-Paclitaxel · Drug: Gemcitabine

  • Experimental
    nab-Paclitaxel plus Carboplatin

    Treatment Arm B: nab-Paclitaxel 125 mg/m\^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration

    Drug: nab-Paclitaxel · Drug: Carboplatin

  • Active comparator
    Gemcitabine plus Carboplatin

    Treatment Arm C: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration

    Drug: Carboplatin · Drug: Gemcitabine

Interventions

  • nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.

    Also known as: Abraxane

  • Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration

    Also known as: Paraplatin,, Paraplatin AQ

  • Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.

    Also known as: Gemzar

07

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.

    PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.

    Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C

Secondary outcomes

  1. Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.

    Percentage of participants with an Objective Complete or Partial Overall Response according to RECIST 1.1 and defined as: Complete response-disappearance of all target lesions; partial response at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.

    Time frame: Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C

  2. Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy

    The percentage of participants who initiated Cycle 6 receiving doublet combination therapy regardless of the need for dose modifications.

    Time frame: Cycle 6

  3. Kaplan-Meier Estimates of Overall Survival

    Overall survival was defined as the time from the date of randomization to the date of death (from any cause).

    Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C

  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Treatment-emergent adverse events (TEAEs) were defined as any AEs that began or worsened with the onset date on or after the date of the first dose of IP through 28 days after the last dose. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on the participant's symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity as follows: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death.

    Time frame: From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C

  5. Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions)

    The number of participants with dose modifications occurring during the treatment period. Dose reductions and interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

    Time frame: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C

  6. Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs

    Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen with an onset date on or after the date of the first dose of IP through 28 days after the last dose.

    Time frame: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C

08

Results

Posted Mar 8, 2018
Limitations and caveats
Due to changes in the treatment landscape since the trial initiation, including the initiation of trials with immunotherapy drugs, successful enrollment of the Phase 3 part was considered unlikely and was not conducted; no safety signals were raised.

Participant flow

This multicenter study was conducted by investigators in 11 countries in North America, Europe, Australia and South America, and enrolled participants at a total of 86 sites. Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.

Participant flow — Overall Study
MilestoneArm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
Started616466
Safety population606464
Treatment discontinued606464
Completed000
Not completed616466
Withdrew: Death201
Withdrew: Adverse event91312
Withdrew: Progressive disease313536
Withdrew: Symptomatic deterioration331
Withdrew: Withdrawal by subject646
Withdrew: Physician decision436
Withdrew: Non-compliance with study drug120
Withdrew: Given commercially available drug002
Withdrew: Protocol violation110
Withdrew: Miscellaneous330
Withdrew: Untreated: other001
Withdrew: Untreated: death001
Withdrew: Untreated: withdrawal before study start100

Outcome measures

PrimaryKaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.

PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.

Time frame:
From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Reported as:
Median · months
Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.
monthsArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.5.5 (4.1 to 7.0)8.3 (5.7 to 10.6)6.0 (4.7 to 7.2)
Statistical analysis
  • Arm A: Nab-Paclitaxel + Gemcitabine vs Arm B: Nab-Paclitaxel + Carboplatin · Log Rank · p = 0.0183 · Hazard ratio (hr): 1.692 · 95% CI 1.089 to 2.629
  • Arm B: Nab-Paclitaxel + Carboplatin vs Arm C: Gemcitabine + Carboplatin · Log Rank · p = 0.0152 · Hazard ratio (hr): 0.581 · 95% CI 0.373 to 0.904
  • Arm A: Nab-Paclitaxel + Gemcitabine vs Arm C: Gemcitabine + Carboplatin · Log Rank · p = 0.8599 · Hazard ratio (hr): 1.039 · 95% CI 0.676 to 1.597
SecondaryPercentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.

Percentage of participants with an Objective Complete or Partial Overall Response according to RECIST 1.1 and defined as: Complete response-disappearance of all target lesions; partial response at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.

Time frame:
Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.
percentage of participantsArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.39.3 (27.1 to 52.7)73.4 (60.9 to 83.7)43.9 (31.7 to 56.7)
SecondaryPercentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy

The percentage of participants who initiated Cycle 6 receiving doublet combination therapy regardless of the need for dose modifications.

Time frame:
Cycle 6
Reported as:
Number · percentage of participants
Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy
percentage of participantsArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy55.7 (42.5 to 68.5)64.1 (51.1 to 75.7)50.0 (37.4 to 62.6)
SecondaryKaplan-Meier Estimates of Overall Survival

Overall survival was defined as the time from the date of randomization to the date of death (from any cause).

Time frame:
From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Reported as:
Median · months
Kaplan-Meier Estimates of Overall Survival
monthsArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
Kaplan-Meier Estimates of Overall Survival12.1 (9.4 to 15.9)16.8 (11.3 to 20.6)12.6 (10.1 to 16.6)
Statistical analysis
  • Arm A: Nab-Paclitaxel + Gemcitabine vs Arm B: Nab-Paclitaxel + Carboplatin · Log Rank · p = 0.1579 · Hazard ratio (hr): 1.375 · 95% CI 0.882 to 2.143
  • Arm B: Nab-Paclitaxel + Carboplatin vs Arm C: Gemcitabine + Carboplatin · Log Rank · p = 0.2945 · Hazard ratio (hr): 0.796 · 95% CI 0.520 to 1.221
  • Arm A: Nab-Paclitaxel + Gemcitabine vs Arm C: Gemcitabine + Carboplatin · Log Rank · p = 0.6691 · Hazard ratio (hr): 1.101 · 95% CI 0.710 to 1.708
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Treatment-emergent adverse events (TEAEs) were defined as any AEs that began or worsened with the onset date on or after the date of the first dose of IP through 28 days after the last dose. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on the participant's symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity as follows: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death.

Time frame:
From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
Any TEAE606364
Any Grade 3 or Higher TEAE465154
Treatment-related TEAE596260
Treatment-related, Grade 3 or Higher TEAE354346
Serious TEAE222025
Treatment-related Serious TEAE10913
TEAE Leading to Discontinuation (D/C) of IP162915
Treatment Related (TR) TEAE Leading to D/C of IP122712
TEAE Leading to Dose Reduction (DR) of IP232025
Treatment related TEAE Leading to DR of IP232023
TEAE Leading to Dose Interruption (DI) of IP315050
TR TEAE Leading to DI of IP274444
TEAE leading to D/C of nab-Paclitaxel16170
TR TEAE leading to D/C of nab-Paclitaxel11130
TEAE leading to DR of nab-Paclitaxel22190
TR TEAE leading to DR of nab-Paclitaxel21190
TEAE leading to DI of nab-Paclitaxel31500
TR TEAE leading to DI of nab-Paclitaxel27440
TEAE leading to D/C of Gemcitabine13013
TR TEAE leading to D/C of Gemcitabine709
TEAE leading to DR of Gemcitabine18025
TR TEAE leading to DR of Gemcitabine18023
TEAE leading to DI of Gemcitabine31049
TR TEAE leading to DI of Gemcitabine24043
TEAE leading to D/C of Carboplatin02815
TR TEAE leading to D/C of Carboplatin02512
TEAE leading to DR of Carboplatin01721
TR TEAE leading to DR of Carboplatin01720
TEAE leading to DI of Carboplatin05050
TR TEAE leading to DI of Carboplatin04443
TEAE Leading to Death212
Treatment Related TEAE leading to death101
SecondaryPercentage of Participants Experiencing Dose Modifications (Reductions and Interruptions)

The number of participants with dose modifications occurring during the treatment period. Dose reductions and interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

Time frame:
From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions)
percentage of participantsArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
≥ one DR for both IPs33.346.951.6
≥ one DI for both IPs38.370.373.4
≥ one dose missed for both IPs48.345.356.3
SecondaryPercentage of Participants Who Discontinued From All Study Treatment Due to TEAEs

Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen with an onset date on or after the date of the first dose of IP through 28 days after the last dose.

Time frame:
From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs
percentage of participantsArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs21.7 (12.1 to 34.2)26.6 (16.3 to 39.1)21.9 (12.5 to 34.0)

Adverse events

Collected over From randomization through to 28 days after the last dose of IP; up to the data cut-off date of 16 December 2016; AEs collected and monitored for 39 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nab-Paclitaxel + Gemcitabine—22/60 (36.7%)59/60 (98.3%)
Arm B: Nab-Paclitaxel + Carboplatin—20/64 (31.3%)63/64 (98.4%)
Arm C: Gemcitabine + Carboplatin—25/64 (39.1%)62/64 (96.9%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
PyrexiaGeneral disorders4/600/640/64
PneumoniaInfections and infestations4/601/641/64
AnaemiaBlood and lymphatic system disorders2/602/644/64
Febrile neutropeniaBlood and lymphatic system disorders1/603/640/64
NauseaGastrointestinal disorders2/600/640/64
DyspnoeaRespiratory, thoracic and mediastinal disorders2/601/642/64
NeutropeniaBlood and lymphatic system disorders1/602/642/64
ThrombocytopeniaBlood and lymphatic system disorders0/600/642/64
Non-cardiac chest painGeneral disorders0/600/642/64
Respiratory tract infectionInfections and infestations0/600/642/64
Most frequent other events
Showing 10 of 88
Most frequent other events
EventArm A: Nab-Paclitaxel + GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + Carboplatin
NeutropeniaBlood and lymphatic system disorders24/6043/6444/64
FatigueGeneral disorders33/6032/6424/64
AlopeciaSkin and subcutaneous tissue disorders33/6025/647/64
ThrombocytopeniaBlood and lymphatic system disorders8/6018/6434/64
NauseaGastrointestinal disorders26/6034/6427/64
AnaemiaBlood and lymphatic system disorders25/6033/6430/64
ConstipationGastrointestinal disorders13/6027/6425/64
DiarrhoeaGastrointestinal disorders25/6026/6413/64
VomitingGastrointestinal disorders18/6013/6411/64
Oedema peripheralGeneral disorders17/6012/6410/64

Baseline characteristics

Intent-to-treat (ITT) population includes all randomized participants regardless of whether they received any IP or had any efficacy assessments collected.

Age, Continuous
Age, Continuous(years)Arm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + CarboplatinTotal
Mean53.7 ± 12.1654.3 ± 11.9656.7 ± 10.8754.9 ± 11.67
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + CarboplatinTotal
Female616466191
Male0000
Race
Race(Participants)Arm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + CarboplatinTotal
Black or African American96823
White505554159
Unknown or Not Reported2349
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Arm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + CarboplatinTotal
0 = Fully Active343842114
1 = Restrictive but ambulatory25262273
2 = Ambulatory but unable to work1001
Missing1023
Disease Free Interval by Clinical Interpretation
Disease Free Interval by Clinical Interpretation(Years)Arm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + CarboplatinTotal
≤ 1 year17162053
> 1 year434845136
Missing1012
Time from Diagnosis to First Documented Disease/Relapse
Time from Diagnosis to First Documented Disease/Relapse(months)Arm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + CarboplatinTotal
Mean38.8 ± 49.4629.9 ± 37.1850.9 ± 62.6040.0 ± 51.46
Time from First Documented Metastatic Disease/Relapse to Study Randomization
Time from First Documented Metastatic Disease/Relapse to Study Randomization(months)Arm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + CarboplatinTotal
Mean2.1 ± 5.084.2 ± 18.391.6 ± 1.702.6 ± 11.07
Time from Primary Diagnosis to Randomization
Time from Primary Diagnosis to Randomization(months)Arm A: Nab-Paclitaxel Plus (+) GemcitabineArm B: Nab-Paclitaxel + CarboplatinArm C: Gemcitabine + CarboplatinTotal
Mean43.7 ± 54.6035.5 ± 40.5152.5 ± 62.3744.0 ± 53.53

4 further baseline measures are reported on the registry.

09

Study locations

140 sites
  • Ironwood Cancer and Research Center
    Chandler, Arizona 85224, United States
  • Arizona Center for Cancer Care
    Glendale, Arizona 85306, United States
  • Arizona Cancer Research Alliance
    Scottsdale, Arizona 85251, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Pacific Cancer Medical Center Inc
    Anaheim, California 92801, United States
  • California Cancer Associates for Research and Excellence cCARE
    Escondido, California 92025, United States
  • University of California San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Wilshire Oncology Medical Group, Inc
    La Verne, California 91750, United States
  • Translational Research Management
    Los Angeles, California 90045, United States
  • Coastal Integrative Cancer Care
    San Luis Obispo, California 93401, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • Redwood Regional Medical Group, INC
    Santa Rosa, California 95403, United States
  • Center for Hematology-Oncology
    Boca Raton, Florida 33486, United States
  • Memorial Breast Cancer Center
    Hollywood, Florida 33021, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • University of Miami School of Medicine
    Miami, Florida 33136, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Joliet Oncology-Hematology Associates, Ltd
    Joliet, Illinois 60435, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Investigative Clinical Research of Indiana, LLC
    Indianapolis, Indiana 46254, United States
  • University of South Alabama Mitchell Cancer Institute
    Lafayette, Louisiana 70503, United States
  • University of Maryland School of Med
    Baltimore, Maryland 21201, United States
  • Center for Cancer and Blood Disorders, PC
    Bethesda, Maryland 20817, United States
  • Henry Ford Medical Center - New Center One
    Detroit, Michigan 48202-268, United States
  • Minnesota Oncology Hematology, PA
    Minneapolis, Minnesota 55407, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Midwest Physicians Group
    Kansas City, Missouri 64132, United States
  • Missouri Baptist Medical Center
    Saint Louis, Missouri 63131, United States
  • New Hampshire Oncology Hematology
    Hooksett, New Hampshire 03106, United States
  • Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
  • Englewood Hospital and Medical Center
    Englewood, New Jersey 07631, United States
  • Hematology Oncology Associates of CNY
    East Syracuse, New York 13057, United States
  • NYU Langone Arena Oncology
    Lake Success, New York 11042, United States
  • Clinical Research Alliance
    New York, New York 10021, United States
  • Alamance Regional Medical Cancer Center
    Burlington, North Carolina 27215-8700, United States
  • University of Cincinnatti
    Cincinnati, Ohio 45219, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • Mark H Zangmeister Center
    Columbus, Ohio 43219, United States
  • Toledo Community Oncology Program
    Toledo, Ohio 43623, United States
  • Cancer Centers of Southwest Oklahoma
    Lawton, Oklahoma 73505, United States
  • North Bend Medical Center
    Coos Bay, Oregon 97420, United States
  • Northwest Cancer Specialists, P.C. - Hoyt
    Portland, Oregon 97213, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • St Mary Medical Center
    Langhorne, Pennsylvania 19047, United States
  • Magee Women's Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • South Carolina Oncology Associates
    Columbia, South Carolina 29210, United States
  • Chattanooga Oncology Hematology Associates
    Chattanooga, Tennessee 37404, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Texas Oncology, PA
    Dallas, Texas 75231, United States
  • Texas Oncology, PA- Dallas
    Dallas, Texas 75246, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • UT Physicians General Medicine
    Houston, Texas 77030, United States
  • Cancer Care Centers of South Texas - Loop
    San Antonio, Texas 78217, United States
  • Texas Oncology P.A.- Tyler
    Tyler, Texas 75702, United States
  • Hematology Oncology Associates of Fredericksburg
    Fredericksburg, Virginia 22408, United States
  • Delta Hematologyoncology Associates
    Portsmouth, Virginia 23704, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
  • Edwards Comprehensive Cancer Center
    Huntington, West Virginia 25701, United States
  • Saint Vincent Hospital
    Green Bay, Wisconsin 54301, United States
  • Columbia St Marys Cancer Center
    Milwaukee, Wisconsin 53211, United States
  • Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Frankston Hospital Oncology Research
    Frankston, Victoria 3199, Australia
  • Border Medical Oncology
    Wodonga, Victoria 3690, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, 6009, Australia
  • Universitaetsklinik Innsbruck
    Innsbruck, 6020, Austria
  • Salzburger Landkliniken St. Johanns-Spital
    Salzburg, 5020, Austria
  • Medizinische Universitat Wien
    Vienna, 1090, Austria
  • Centro de Oncologia Da Bahia
    Salvador, Bahia 41820-021, Brazil
  • Liga Paranaense de Combate Ao Cancer
    Curitiba, Paraná 81520-060, Brazil
  • Instituto Nacional de Cancer - INCA
    Rio De Janerio, Rio De Janeiro 20560-120, Brazil
  • Associacao Hospitalar Moinhos de Vento Hospital Moinhos de Vento
    Porto Alegre, Rio Grande Do Sul 90035-001, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Fundacao Pio XII - Hospital de Cancer de Barretos
    Barretos, São Paulo 14784-400, Brazil
  • Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú
    Jau/SP, São Paulo 17210-080, Brazil
  • ONCOCLINIC Clinica de Oncologia LTDA
    Fortaleza, 60160-230, Brazil
  • Instituto Ribeiraopretano de Combate Ao Cancer
    Ribeirao Preto, 14015-130, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da USP
    Ribeirao Preto, 14048-900, Brazil
  • Hospital Bruno Born
    Rio Grande Do Sul, 95900-000, Brazil
  • Hospital de Base Da Faculdade de Medicina de
    Sao Jose Do Rio Preto, 15090-000, Brazil
  • Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira
    Sao Paulo, 05651-901, Brazil
  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
    São Paulo, 01308-050, Brazil
  • Instituto Brasileiro de Controle Do Cancer IBCC
    São Paulo, 03102-002, Brazil
  • Ottawa General Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • CHUM - Notre Dame
    Montreal, Quebec H2L 4M1, Canada
  • Hospital du Saint Scarement Sacrement Laboratory
    Quebec City, Quebec G1S4L8, Canada
  • CSSS de Rimouski Neigette
    Rimouski, Quebec G5L5T1, Canada
  • Alan Blair Cancer Centre at Pasqua Hosptial
    Regina, Saskatchewan S4T1A5, Canada
  • Centre Jean Perrin
    Clermont-Ferrand, 63003, France
  • Sankt Gertrauden-Krankenhaus
    Berlin, 10713, Germany
  • Facharztpraxis fur Gynakologie und Geburtshilfe
    Bonn, 53111, Germany
  • Agaplesion Markus Krankenhaus
    Frankfurt, 60431, Germany
  • Praxis fur interdisziplinare Onkologie & Hamatologie
    Freiburg, 79110, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Frauenarzte am Bahnhofsplatz
    Hildesheim, 31134, Germany
  • Schwerpunktpraxis fur Gynakologische Onkologie
    Köln, 50679, Germany
  • LMU Klinikum der Universitat
    München, 81377, Germany

Showing the first 100 of 140 sites across 12 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Gluck S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7. Erratum In: Trials. 2016 Feb 03;17:63. doi: 10.1186/s13063-016-1195-6. PubMed 26673577 ↗
  • Liu MC, Janni W, Georgoulias V, Yardley DA, Harbeck N, Wei X, McGovern D, Beck R. First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial. Cancer Manag Res. 2019 Dec 12;11:10427-10433. doi: 10.2147/CMAR.S208712. eCollection 2019. PubMed 31849532 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2013 to primary completion in Oct 2016, 37 months.

Results were first posted in Mar 2018, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2013
First posted
Jun 19, 2013
StartActual
Sep 26, 2013
Primary completionActual
Oct 28, 2016
CompletionActual
Oct 28, 2016
Results first posted
Mar 8, 2018
Last update
Feb 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01881230
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 19, 2013
Start date
Sep 26, 2013
Primary completion
Oct 28, 2016
Completion
Oct 28, 2016
Results posted
Mar 8, 2018
Last update
Feb 21, 2019

Study contacts

Ileana Elias, M.D.
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Carboplatin · Gemcitabine

Start the discussion